Ovid Therapeutics Inc. — Form 8-K
Filed July 8, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Form 8-K filed 2026-07-08 reporting Item 5.02 event (departure of directors/officers or compensatory arrangements) with period of report 2026-07-05. The filing header indicates executive/officer changes and related compensation matters, but specific names, amounts, dates, or details of the departure/arrangement are not provided in the metadata excerpt.
Why this rating
Standard Item 5.02 disclosure; company size $22.2M. Without specifics (name/amount/role/exit details), appears routine officer transition. Material only if C-level/founder departure with severance significant vs. market cap.
Extracted items
See more from July 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.